hypothesis that pharmacological agents capable of producing an inward shift in the balance of current in the early phases of the epicardial AP, either by inhibiting transient outward current (I to ; quinidine) or augmenting I Ca (cilostazol and milrinone), can protect against hypothermia-induced VT/VF in the setting of ER.
Methods

Arterially Perfused Wedge of Canine Left Ventricle
We used floating glass microelectrode techniques to record APs simultaneously from 2 epicardial (Epi1 and Epi2) and 1 endocardial site in coronary-perfused wedge preparations isolated from the inferior and lateral regions of the canine left ventricle (LV), together with pseudo-ECG recorded across the bath along the endocardial-epicardial axis. Detailed methods are provided in the Data Supplement. The Tyrode's solution was warmed while passing through the heated coils to deliver the perfusate at 37°C. To simulate hypothermia, the solution was redirected to 2 coiled-perfusion lines in series immersed in beakers filled with water, before reaching the tissues. We lowered the temperature of the perfusate to 32°C.
Measurements of AP Parameters
The epicardial AP notch magnitude (phase 1 magnitude/phase 0 am-plitude×100), phase 0 to phase 2 interval (time between the first 2 peaks of the derivative of the AP), as well as the notch index (notch magnitude×[Ph 0-Ph 2 interval]), which approximates the area of the notch, were measured in AP recordings as previously described (Figure 1 ). 11
J-Wave Area Calculations
The area of the J wave was calculated as follows: The start of J wave was defined using derivative of the ECG signal. In case of clear separation, it was set at the time when this derivative is zero which corresponds to the notch between R wave and J wave. When this separation was not clearly visible, this time was set at the moment when the negative derivative attains its maximal value (ie, minimal rate of decline) after the maximal downslope of the R wave. The J-wave area was expressed as millivolt×millisecond ( Figure 1 ).
Statistical Analysis
Results are presented as mean±SEM throughout the article. Statistical comparisons were made using Student t test for effect of hypothermia on action potential duration at 90% of repolarization, maximum epicardial dispersion of repolarization, transmural dispersion of repolarization, notch index, notch magnitude, notch duration, and J wave area and effect of hypothermia on these parameters in the setting of ER (Table) . One-way repeated measures ANOVA was used for effects of quinidine, cilostazol, and milrinone (Table) , followed by pairwise comparisons corrected by Bonferroni method.
Results
Effects of Hypothermia in LV Wedge Preparation
In an initial series of 7 experiments, we examined the effects of hypothermia in coronary-perfused canine LV wedge preparations. Lowering the temperature to 32°C to 34°C caused prolongation of AP durations and accentuation of the AP notch in the epicardium but not endocardium, thus augmenting the amplitude of the J wave ( Figure 2 , Table) . Under baseline condition, lowering the temperature to 32°C failed to cause loss of the epicardial AP dome or to induce arrhythmic activities.
Effects of Hypothermia in ER-Induced LV Wedge Preparation
Because vagal influences are known to accentuate the electrocardiographic and arrhythmic manifestations of ER, [12] [13] [14] in a second series of experiments, we induced an ER phenotype using a combination of the I to activator NS5806 (3-10 μmol/L), the Ca 2+ channel blocker verapamil (1 μmol/L), and acetylcholine (3 μmol/L) added to the coronary perfusate. The combination accentuated the AP notch in epicardium but not endocardium, thus leading to augmentation of the electrocardiographic J wave but no arrhythmia (Figure 3A) . Hypothermia caused a further increase of J-wave area, notch magnitude, and notch index, leading to all-ornone repolarization at the end of phase 1 of the epicardial AP. Loss of the epicardial AP dome at some sites but not others resulted in a prominent increase in epicardial dispersion of repolarization and transmural dispersion of repolarization. The voltage gradient between the abbreviated epicardial AP and the relatively normal endocardial AP produced a prominent ST-segment elevation. A prominent AP duration gradient developed between sites displaying a normal AP dome and adjacent sites where the dome was lost, thus creating a vulnerable window within epicardium as well as between epicardium and endocardium across the ventricular wall. Propagation of the dome from regions at which it was maintained to regions, at which it was lost, caused local re-excitation via a phase 2 reentry mechanism, leading to the development of closely coupled extrasystoles and polymorphic VT/VF ( Figure 3 ). Similar results were obtained in 12 experiments. Composite of the AP and electrocardiographic parameters are presented in Figure 3 and the Table. 
Effect of Quinidine, Cilostazol, and Milrinone to Suppress and Prevent Hypothermia-Induced Arrhythmogenesis
Quinidine has been shown to restore transmural electric homogeneity and abort arrhythmic activity in the J-wave syndromes. 2 In another series of 5 experiments, we tested the hypothesis that quinidine could prevent the hypothermiainduced VT/VF developing in the setting of ER attributable to its effect to reduce the I to . VT/VF was first induced by exposure of the LV wedge to hypothermia+NS5806 (3-10 μmol/L)+verapamil (1 μmol/L)+acetylcholine (3 μmol/L). Temperature was then restored to 37°C, at which point the arrhythmia subsided. Quinidine (5 μmol/L) was then added to the coronary perfusate, and hypothermia was reinduced. Quinidine (5 μmol/L) diminished the AP notch and J wave at 37°C and prevented loss of the epicardial AP dome and development of the repolarization abnormalities, thus preventing the development of phase 2 reentry and VT/VF when temperature was reduced to 32°C (Figure 4) . A similar effect of quinidine to prevent VT/VF was observed in 5 of 5 preparations exposed to hypothermia (Figure 4 and Table) . In 2 experiments, quinidine (5-10 μmol/L) was added during the VT/VF episode at 32°C. In both cases, the drug suppressed all arrhythmic activity and restored electric homogeneity throughout the preparation.
In a final series of experiments, we examined the effectiveness of the phosphodiesterase III inhibitors cilostazol and A, The first grouping shows recordings from 2 epicardial (Epi) and 1 endocardial (Endo) sites, together with a pseudo-ECG after exposure of the left ventricular wedge to NS5806 (3-10 μmol/L)+verapamil (1 μmol/L)+acetylcholine (ACh; 3 μmol/L). In the second grouping, the coronary perfusate temperature was lowered to 32°C, leading to development of VT/VF. Temperature was then restored to 37°C, at which point the arrhythmia subsided (not shown). The third grouping was recorded after addition of quinidine (5 μmol/L) and reinduction of hypothermia. Quinidine (5 μmol/L) diminished the action potential (AP) notch and J wave at 37°C and prevented loss of the Epi AP dome and development of the repolarization abnormalities, thus preventing the development of phase 2 reentry and VT/VF when temperature was reduced to 32°C. B to F, Composite data showing the effect of lowering coronary perfusate temperature to 32°C on AP duration at 90% repolarization (APD 90 ), notch magnitude, notch index, and J-wave area in the presence and absence of quinidine. All recordings were obtained at a basic cycle length of 1000 ms. EDR indicates epicardial dispersion of repolarization; and TDR, transmural dispersion of repolarization. Results are mean±SEM. *P<0.05. †P<0.01 vs NS5806+verapamil+ACh combination. n=5 for B, C, D, E, and F. milrinone to prevent hypothermia-induced VT/VF in the setting of ER. These agents are known to augment I Ca via their action to increase cAMP. Here again, we first demonstrated the ability of the combination of provocative agents and hypothermia (32°C) to accentuate ER, thus creating a large epicardial and transmural dispersion of repolarization giving rise to phase 2 reentry and VT/VF. We then restored temperature to 37°C, which reversed the repolarization abnormality and suppressed VT/VF. The addition of cilostazol (10 μmol/L) or milrinone (5 μmol/L) reduced the epicardial AP notch at 37°C and prevented the repolarization abnormality as well as the development of phase 2 reentry and A, The first grouping shows recordings from 2 epicardial (Epi) and 1 endocardial (Endo) sites, together with a pseudo-ECG after exposure of the left ventricular wedge to NS5806 (3-10 μmol/L)+verapamil (1 μmol/L)+acetylcholine (ACh; 3 μmol/L). In the second grouping, the coronary perfusate temperature was lowered to 32°C, leading to development of VT/VF. Temperature was then restored to 37°C, at which point the arrhythmia subsided (not shown). The third grouping was recorded after addition of cilostazol (10 μmol/L) and reinduction of hypothermia. Cilostazol (10 μmol/L) diminished the action potential (AP) notch and J wave at 37°C and prevented loss of the Epi AP dome and development of the repolarization abnormalities, thus preventing the development of phase 2 re-entry and VT/VF in 5 of 7 preparations when temperature was reduced to 32°C. B to F, Composite data showing the effect of lowering coronary perfusate temperature to 32°C on AP duration at 90% repolarization (APD 90 ), notch magnitude, notch index, and J-wave area in the presence and absence of cilostazol. EDR indicates epicardial dispersion of repolarization; TDR, transmural dispersion of repolarization. All recordings were obtained at a basic cycle length of 1000 ms. Results are mean±SEM. *P<0.05. †P<0.01 vs NS5806+verapamil+ACh combination. n=5 for B, C, D, E, and F. February 2014 VT/VF when temperature was once again reduced to 32°C (Figures 5 and 6 ). Both agents prevented the hypothermiainduced increase in transmural dispersion of repolarization, epicardial dispersion of repolarization, epicardial AP notch magnitude, notch index, and J-wave area on pseudo-ECG. Cilostazol was successful in preventing the VT/VF in 5 of 7 preparations. Similarly, milrinone (5 μmol/L) prevented the hypothermia-induced VT/VF in 5 of 7 preparations ( Figures 5 and 6 , Table) .
Discussion
Therapeutic hypothermia is today widely used to prevent tissue injury secondary to cardiac arrest, ischemic stroke, traumatic brain and spinal cord injury, and neurogenic fever A, The first grouping shows recordings from 2 epicardial (Epi) and 1 endocardial (Endo) sites, together with a pseudo-ECG after exposure of the left ventricular wedge to NS5806 (3-10 μmol/L)+verapamil (1 μmol/L)+acetylcholine (ACh; 3 μmol/L). The coronary perfusate temperature was lowered to 32°C, leading to development of VT/VF. Temperature was then restored to 37°C, at which point the arrhythmia subsided (not shown). The third grouping was recorded after addition of milrinone (5 μmol/L) and reinduction of hypothermia. Milrinone (5 μmol/L) diminished the action potential (AP) notch and J wave at 37°C and prevented loss of the Epi AP dome and development of the repolarization abnormalities, thus preventing the development of phase 2 reentry and VT/VF in 5 or 7 preparations when temperature was reduced to 32°C. B to E, Composite data showing the effect of lowering coronary perfusate temperature to 32°C on AP duration at 90% repolarization (APD 90 ), notch magnitude, notch index, and J-wave area in the presence and absence of milrinone. EDR indicates epicardial dispersion of repolarization; and TDR, transmural dispersion of repolarization. All recordings were obtained at a basic cycle length of 1000 ms. Results are mean±SEM. *P<0.05. †P<0.01 vs NS5806+verapamil+ACh combination. n=5 for B, C, D, E, and F. following brain trauma. Subjects are generally cooled to a target temperature of 32°C to 34°C (90°F-93°F). 15, 16 In cases of cardiac arrest, the Hypothermia after Cardiac Arrest Study Group 17 reported that 55% of 137 patients in the hypothermia group experienced favorable outcomes, compared with only 39% in the group that received standard care following resuscitation. Among the adverse events encountered with therapeutic hypothermia is the development of cardiac arrhythmias. 9, 10 Hypothermia's adverse events increase in severity the lower a patient's body temperature is reduced. The accepted medical standard is to not drop <32°C (90°F). 18 The factors that predispose to hypothermia-induced arrhythmogenesis and the mechanisms involved are poorly understood. Recent studies report an association between ER and the development of hypothermia-induced VT/VF. 9, 10 The present study recapitulates this clinical phenomenon in an experimental model consisting of the canine LV coronary-perfused LV wedge preparation, provides a mechanistic understanding of the cellular basis for the development of VT/VF in the setting of ER and hypothermia, and identifies potential therapeutic agents that may be useful in suppressing or preventing the development of hypothermiainduced VT/VF.
Mechanism of Hypothermia-Induced Arrhythmias in Patients With ER Syndrome
The J-wave syndrome, which includes both Brugada and ER syndromes, has been associated with genetic defects that cause a gain of function of I to and a loss of function of I Ca among many others. 4 Both syndromes are also known to be aggravated by increased vagal tone. 12, 13 In this study, we pharmacologically mimicked these genetic and autonomic factors to create ER using the I to agonist NS5806 (3-10 μmol/L), I Ca antagonist verapamil (1 μmol/L), and acetylcholine (3 μmol/L). Acetylcholine contributes to the generation of the ER syndrome phenotype by causing both indirect (via accentuated antagonism) and direct use-dependent inhibition of I Ca . 19 Litovsky and Antzelevitch 19 demonstrated in 1990 the ability of acetylcholine to accentuate thee epicardial AP notch and to cause loss of AP dome.
Under baseline conditions, lowering temperature to 32°C caused the appearance of prominent J wave in the ECG attributable to accentuation of the epicardial AP notch. In the absence of provocative agents designed to generate an ER pattern in the ECG, no arrhythmic activity was observed in any of the preparations. After the generation of the ER phenotype, relatively mild hypothermia (32°C-34°C) caused all-or-none repolarization, leading to loss of the AP dome at some epicardial sites but not others. This resulted in dispersion of AP repolarization both within epicardium and between epicardium and endocardium. Propagation of the AP dome, from sites at which the dome was maintained to sites at which it was lost, caused local re-excitation via a phase 2 reentry mechanism, leading to the development of closely coupled extrasystoles and VT/VF. Consistent with these observations is the demonstration by Nishida et al 20 that vagal nerve stimulation accentuates the hypothermia-induced spike and dome AP morphology in canine epicardium.
Hypothermia is thought to accentuate the AP notch attributable to the difference in the Q10 for activation of I to and I Ca . The greater slowing of I Ca activation leaves I to less opposed, thus accentuating phase 1 repolarization and the AP notch. Thus, an effective strategy to reduce the impact of hypothermia would be to either reduce I to or augment I Ca , thus producing an inward shift in the balance of current during the early phase of the AP. In 3 experimental series, we tested this hypothesis by pretreating the preparations with either quinidine to block I to or cilostazol and milrinone to augment I Ca .
Potential Therapeutic Interventions
In support of our hypothesis, quinidine (5 μmol/L) proved capable of both suppressing and preventing the hypothermiainduced VT/VF in all preparations in which the drug was tested. Cilostazol (10 μmol/L) and milrinone (5 μmol/L) were effective in preventing the hypothermia-induced VT/VF in most but not all preparations. These agents increase I Ca secondary to an increase in cAMP. It is noteworthy that cilostazol was reported to be able to prevent VT/VF in a patient with ER syndrome for an extended period of time. 21 A beneficial effect of milrinone has as yet not been reported.
Conclusions
The present study demonstrates the effect of hypothermia to accentuate repolarization abnormalities within the LV epicardium and that in the setting of ER, this effect of hypothermia is accentuated leading to the development of phase 2 reentry and VT/VF. We also provide support for the hypothesis that agents capable of producing an inward shift in the balance of current during the early phases of the AP can exert a protective and/or ameliorative effect. Quinidine, by virtue of its I to inhibition, and cilostazol and milrinone, by virtue of their effects to augment I Ca , are effective in partially reversing the hypothermia-induced repolarization abnormalities, thus restoring electric homogeneity and abolishing the arrhythmogenic substrate.
Study Limitations
As with all data derived from experimental animal models, extrapolation of the data from in vitro models to the clinic must be done with great care.
